Literature DB >> 17503095

Kinetics and mechanism of the reduction of (ImH)[trans-RuCl4(dmso)(Im)] by ascorbic acid in acidic aqueous solution.

Malgorzata Brindell1, Dorota Piotrowska, Azza A Shoukry, Grazyna Stochel, Rudi van Eldik.   

Abstract

A systematic study of the reduction of (ImH)[trans-RuCl(4)(dmso)(Im)] (NAMI-A; dmso is dimethyl sulfoxide, Im is imidazole), a promising antimetastasing agent entering phase II clinical trial, by L-ascorbic acid is reported. The rapid reduction of trans-[Ru(III)Cl(4)(dmso)(Im)](-) results in formation of trans-[Ru(II)Cl(4)(dmso)(Im)](2-) in acidic medium (pH = 5.0) and is followed by successive dissociation of the chloride ligands, which cannot be suppressed even in the presence of a large excess of chloride ions. The reduction of NAMI-A strongly depends on pH and is accelerated on increasing the pH. Over the small pH range 4.9-5.1, the reaction is quite pH-independent and the influence of temperature and pressure on the reaction could be studied. On the basis of the reported activation parameters and other experimental data, it is suggested that the redox process follows an outer-sphere electron transfer mechanism. A small contribution from a parallel reaction ascribed to inner-sphere reduction of aqua derivatives of NAMI-A, was found to be favored by lower concentrations of the NAMI-A complex and higher temperature. In the absence of an excess of chloride ions, the reduction process is catalyzed by the Ru(II) products being formed. The reduction of NAMI-A is also catalyzed by Cu(II) ions and the apparent catalytic rate constant was found to be 1.5 x 10(6) M(-2) s(-1) at 25 degrees C.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17503095     DOI: 10.1007/s00775-007-0234-x

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  24 in total

1.  A kinetic study of the chemical stability of the antimetastatic ruthenium complex NAMI-A.

Authors:  Marjan Bouma; Bastiaan Nuijen; Martine T Jansen; Gianni Sava; Antonella Flaibani; Auke Bult; Jos H Beijnen
Journal:  Int J Pharm       Date:  2002-11-06       Impact factor: 5.875

Review 2.  Metal-based antitumour drugs in the post genomic era.

Authors:  Paul J Dyson; Gianni Sava
Journal:  Dalton Trans       Date:  2006-03-28       Impact factor: 4.390

3.  DNA as a possible target for antitumor ruthenium(III) complexes.

Authors:  E Gallori; C Vettori; E Alessio; F G Vilchez; R Vilaplana; P Orioli; A Casini; L Messori
Journal:  Arch Biochem Biophys       Date:  2000-04-01       Impact factor: 4.013

4.  Molecular interactions of ruthenium complexes in isolated mammalian nuclei and cytotoxicity on V79 cells in culture.

Authors:  A Barca; B Pani; M Tamaro; E Russo
Journal:  Mutat Res       Date:  1999-01-25       Impact factor: 2.433

5.  Dual Action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen.

Authors:  Gianni Sava; Sonia Zorzet; Claudia Turrin; Francesca Vita; MariaRosa Soranzo; Giuliano Zabucchi; Moreno Cocchietto; Alberta Bergamo; Stefano DiGiovine; Gabriella Pezzoni; Luigi Sartor; Spiridione Garbisa
Journal:  Clin Cancer Res       Date:  2003-05       Impact factor: 12.531

6.  Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer.

Authors:  L E Gerweck; K Seetharaman
Journal:  Cancer Res       Date:  1996-03-15       Impact factor: 12.701

7.  The hydrolysis of the anti-cancer ruthenium complex NAMI-A affects its DNA binding and antimetastatic activity: an NMR evaluation.

Authors:  Marina Bacac; Anna C G Hotze; Karlijn van der Schilden; Jaap G Haasnoot; Sabrina Pacor; Enzo Alessio; Gianni Sava; Jan Reedijk
Journal:  J Inorg Biochem       Date:  2004-02       Impact factor: 4.155

8.  A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent.

Authors:  Jeany M Rademaker-Lakhai; Desiree van den Bongard; Dick Pluim; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Cancer Res       Date:  2004-06-01       Impact factor: 12.531

9.  Primary tumor, lung and kidney retention and antimetastasis effect of NAMI-A following different routes of administration.

Authors:  Moreno Cocchietto; Sonia Zorzet; Alenka Sorc; Gianni Sava
Journal:  Invest New Drugs       Date:  2003-02       Impact factor: 3.850

10.  Antiangiogenic properties of selected ruthenium(III) complexes that are nitric oxide scavengers.

Authors:  L Morbidelli; S Donnini; S Filippi; L Messori; F Piccioli; P Orioli; G Sava; M Ziche
Journal:  Br J Cancer       Date:  2003-05-06       Impact factor: 7.640

View more
  5 in total

1.  A QM/MM study of the binding of RAPTA ligands to cathepsin B.

Authors:  Antonella Ciancetta; Samuel Genheden; Ulf Ryde
Journal:  J Comput Aided Mol Des       Date:  2011-06-24       Impact factor: 3.686

2.  Ru binding to RNA following treatment with the antimetastatic prodrug NAMI-A in Saccharomyces cerevisiae and in vitro.

Authors:  Alethia A Hostetter; Michelle L Miranda; Victoria J DeRose; Karen L McFarlane Holman
Journal:  J Biol Inorg Chem       Date:  2011-07-08       Impact factor: 3.358

3.  Electronic structural investigations of ruthenium compounds and anticancer prodrugs.

Authors:  Travis V Harris; Robert K Szilagyi; Karen L McFarlane Holman
Journal:  J Biol Inorg Chem       Date:  2009-04-07       Impact factor: 3.358

4.  The reduction of (ImH)[trans-RuIIICl4(dmso)(Im)] under physiological conditions: preferential reaction of the reduced complex with human serum albumin.

Authors:  Malgorzata Brindell; Iwona Stawoska; Justyna Supel; Andrzej Skoczowski; Grazyna Stochel; Rudi van Eldik
Journal:  J Biol Inorg Chem       Date:  2008-04-26       Impact factor: 3.358

5.  X-ray absorption near edge structure spectroscopy to resolve the in vivo chemistry of the redox-active indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019).

Authors:  Alfred A Hummer; Petra Heffeter; Walter Berger; Martin Filipits; David Batchelor; Gabriel E Büchel; Michael A Jakupec; Bernhard K Keppler; Annette Rompel
Journal:  J Med Chem       Date:  2013-01-31       Impact factor: 7.446

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.